What they found: Half-life: ~6 days (140 to 150 hours) Steady-state reached in 4 weeks Dose-dependent drop in HbA1c (up to 1.4 % at 6 mg) Dose-dependent weight loss (up to 8.9 % at 6 mg after 12 weeks) No serious hypoglycemia Most common adverse effects: GI (nausea 22 to 67 %), hair shedding mildly common at higher doses (telogenic, reversible) Why it matters: The Phase 1b established the pharmacokinetic profile and paved the way for Phase 2 dose-finding studies
Specific triggers for medical consultation include achieving less than 5% body weight reduction after reaching the maintenance dose (for Wegovy, after 12 weeks at 2.4 mg as per FDA labeling), prolonged weight loss plateau despite adherence, or intolerable side effects preventing dose escalation to therapeutic levels
Why formulation matters: Standard powders and pills often deliver less than 10% of the active ingredient to the cells
In my case its a perfect motivation for attaining my further goals
All compounds were administered as once-daily s.c
Its also discussed for its antioxidant activity and signaling effects that may help guide wound-healing and tissue-repair pathways
